L
L. Orsini
Researcher at Bristol-Myers Squibb
Publications - 22
Citations - 1232
L. Orsini is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Docetaxel. The author has an hindex of 11, co-authored 22 publications receiving 874 citations.
Papers
More filters
Journal ArticleDOI
Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study
Joong-Won Park,Minshan Chen,Massimo Colombo,Lewis R. Roberts,Myron Schwartz,Pei-Jer Chen,Masatoshi Kudo,Philip J. Johnson,Samuel Wagner,L. Orsini,Morris Sherman +10 more
TL;DR: The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death.
Journal ArticleDOI
Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance
Ju Dong Yang,William S. Harmsen,Seth W. Slettedahl,Roongruedee Chaiteerakij,Felicity Enders,Terry M. Therneau,L. Orsini,W. Ray Kim,Lewis R. Roberts +8 more
TL;DR: Patients diagnosed with HCC during surveillance had less advanced disease, were more likely to be eligible for potentially curative treatments, and had increased survival times (P < .001).
Journal ArticleDOI
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
Martin Reck,Fiona Taylor,John R. Penrod,Michael DeRosa,Laura Morrissey,Homa Dastani,L. Orsini,Richard J. Gralla +7 more
TL;DR: Nivolumab alleviates symptom burden and improves health status versus docetaxel as second‐line squamous NSCLC treatment and time to first HRQoL deterioration was longer.
Journal ArticleDOI
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative
L. Orsini,Marc L. Berger,William H. Crown,Gregory W. Daniel,Hans-Georg Eichler,Wim G. Goettsch,Jennifer Graff,John Guerino,Pall Jonsson,Nirosha Mahendraratnam Lederer,Brigitta Monz,C. Daniel Mullins,Sebastian Schneeweiss,David Van Brunt,Shirley V. Wang,Richard J. Willke +15 more
TL;DR: A plan is described for making registration of HETE RWE studies routine to improve transparency, trust, and research replicability and to explore the structural and practical challenges to the successful implementation of the recommendations of the ISPOR/ISPE task force for preregistration.
Journal ArticleDOI
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
TL;DR: Nivolumab was found to involve a trade-off between improved patient survival and QALYs, and increased cost, which was found that the use of a PS or Markov model produced very similar estimates of expected cost, outcomes, and incremental cost-utility.